ACHL AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ACHL Current Performance
-1.09%
Achilles therapeutics plc - adr
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ACHL
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
NXTC | Nextcure inc | 2 | 4 | 3 | 3 | 1 | |
TARA | Protara therapeutics inc | 2 | 2 | 4 | 1 | 1 | |
TSVT | 2seventy bio inc | - | 3 | 2 | 1 | 1 | |
OCUL | Ocular therapeutix inc | 2 | 4 | 5 | 3 | 1 | |
ADAP | Adaptimmune therapeutics plc | 3 | 4 | 3 | 2 | 1 |
- NXTC Nextcure incValue 2Trend 4Swing Trading 3Whale Interest 3Dividend 1See more
ACHL Profile
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.